Agilent Technologies, Inc. $A Stake Increased by MassMutual Private Wealth & Trust FSB

MassMutual Private Wealth & Trust FSB raised its holdings in shares of Agilent Technologies, Inc. (NYSE:A) by 32.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,777 shares of the medical research company’s stock after purchasing an additional 438 shares during the period. MassMutual Private Wealth & Trust FSB’s holdings in Agilent Technologies were worth $210,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in A. Valeo Financial Advisors LLC grew its position in shares of Agilent Technologies by 3.0% during the first quarter. Valeo Financial Advisors LLC now owns 3,449 shares of the medical research company’s stock worth $403,000 after acquiring an additional 102 shares during the last quarter. Cary Street Partners Financial LLC grew its position in shares of Agilent Technologies by 2.9% during the first quarter. Cary Street Partners Financial LLC now owns 3,688 shares of the medical research company’s stock worth $431,000 after acquiring an additional 103 shares during the last quarter. Western Pacific Wealth Management LP grew its position in shares of Agilent Technologies by 15.2% during the first quarter. Western Pacific Wealth Management LP now owns 873 shares of the medical research company’s stock worth $102,000 after acquiring an additional 115 shares during the last quarter. Bartlett & CO. Wealth Management LLC lifted its holdings in Agilent Technologies by 5.1% in the first quarter. Bartlett & CO. Wealth Management LLC now owns 2,406 shares of the medical research company’s stock worth $281,000 after purchasing an additional 116 shares during the period. Finally, Brighton Jones LLC lifted its holdings in Agilent Technologies by 2.6% in the first quarter. Brighton Jones LLC now owns 4,784 shares of the medical research company’s stock worth $560,000 after purchasing an additional 121 shares during the period.

Agilent Technologies Stock Performance

Shares of NYSE A opened at $127.67 on Friday. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.71. The stock’s fifty day moving average price is $120.19 and its two-hundred day moving average price is $115.94. Agilent Technologies, Inc. has a one year low of $96.43 and a one year high of $153.84. The firm has a market cap of $36.19 billion, a price-to-earnings ratio of 29.97, a P/E/G ratio of 3.94 and a beta of 1.24.

Agilent Technologies (NYSE:A) last issued its quarterly earnings data on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, meeting analysts’ consensus estimates of $1.37. The firm had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The company’s revenue for the quarter was up 10.1% on a year-over-year basis. During the same period in the prior year, the firm posted $1.32 EPS. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. On average, equities analysts forecast that Agilent Technologies, Inc. will post 5.58 EPS for the current year.

Agilent Technologies Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 22nd. Stockholders of record on Tuesday, September 30th will be given a dividend of $0.248 per share. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date is Tuesday, September 30th. Agilent Technologies’s dividend payout ratio is presently 23.24%.

Insider Buying and Selling at Agilent Technologies

In other news, CEO Padraig Mcdonnell sold 1,508 shares of the company’s stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $117.44, for a total transaction of $177,099.52. Following the completion of the sale, the chief executive officer directly owned 37,448 shares in the company, valued at approximately $4,397,893.12. This represents a 3.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Analyst Ratings Changes

A has been the subject of a number of research analyst reports. Wall Street Zen downgraded shares of Agilent Technologies from a “buy” rating to a “hold” rating in a report on Friday, September 5th. Leerink Partners upped their target price on Agilent Technologies to $135.00 and gave the company a “buy” rating in a report on Friday, May 30th. Barclays restated an “equal weight” rating and issued a $125.00 price objective on shares of Agilent Technologies in a report on Friday, August 29th. TD Cowen increased their price objective on Agilent Technologies to $150.00 and gave the company a “buy” rating in a research report on Thursday, May 29th. Finally, Robert W. Baird raised their target price on Agilent Technologies from $141.00 to $142.00 and gave the stock an “outperform” rating in a research report on Thursday, August 28th. Six research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $140.08.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.